Disruptive Tech Research
  • About
  • Media
  • Research
  • Subscribe
  • Log in
Select Page
PRVB: Three Key Takeaways From The FDA Delay

PRVB: Three Key Takeaways From The FDA Delay

by Lou Basenese | Jul 7, 2021 | PRVB

Here are three key takeaways from the FDA’s response to Provention Bio (PRVB)’s BLA application for teplizumab…

PRVB: What To Expect This Week

PRVB: What To Expect This Week

by Lou Basenese | Jun 28, 2021 | PRVB

Here’s what to expect this week from Provention Bio (PRVB) as the FDA’s original PDUFA date hits on Friday…

PRVB: Hold Nose, Buy More

PRVB: Hold Nose, Buy More

by Lou Basenese | Apr 9, 2021 | PRVB

Provention Bio (PRVB) announced the FDA needs more PK/PD data. Here’s why I’m buying more on this pullback…

Provention Drops The F Bomb… Again

Provention Drops The F Bomb… Again

by Lou Basenese | Jan 13, 2021 | PRVB

Provention Bio (PRVB) announced an offering after the bell yesterday, on a day teh stock hit a 52-week high. Here’s what I plan to do…

PRVB: What To Expect This Week

[Trade Alert] Happily Wrong

by Lou Basenese | Jun 18, 2020 | PRVB

Provention Bio (PRVB) successfully priced a $100 million offering. Here are all the details, along with three key data takeaways from the ADA meeting…

Provention Drops The F Bomb… Again

[Trade Alert] Provention Bio (PRVB) Drops The F Bomb

by Lou Basenese | Jun 17, 2020 | PRVB

Provention Bio (PRVB) announced an offering after the bell yesterday on the heel’s of new data for its Type 1 Diabetes treatment. Here’s what I recommend…

« Older Entries

Your account

Sign in

Research Links

  • Real-Time Blog
  • Active Recs
  • Archive

Recent Posts

  • Q2 2022 Portfolio Review & Outlook
  • ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report
  • [IMNM] Biotech Absurdity
  • [Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
  • [Video] ATOM: 5 Key Takeaways From The Q4 2021 Report
  • RESN: Time To Lock In Our 5G Gains
  • [CUE] “That Data Is Amazing!” So Why Is The Stock Down?